SCHEMBL5456073

SCHEMBL5456073

NC(=O)c1c(NC(=O)C2CC2)sc2c(Cl)c(O)ccc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.46
AURKA O14965 1/20 0.45
AURKB Q96GD4 1/20 0.45
MAPK10 P53779 2/20 0.44
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
GSK3B P49841 2/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
TNIK Q9UKE5 1/20 0.36
MAPK1 P28482 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448926 0.86 FLT3 (0.47) FLT3AURKAAURKBMAPK10KMT2A
SCHEMBL5467596 0.85 GRM1 (0.42) AURKAAURKBKMT2AMEN1MAPT
SCHEMBL5458422 0.82 AURKA (0.46) FLT3AURKAAURKBMAPK10KMT2A
SCHEMBL5446326 0.81 MEN1 (0.48) FLT3AURKAAURKBMAPK10KMT2A
SCHEMBL5456366 0.79 FLT3 (0.52) FLT3AURKBKMT2AMEN1MAPT
SCHEMBL14361087 0.79 AURKA (0.42) FLT3AURKAAURKBMAPK10MAPT
SCHEMBL5466113 0.78 FLT3 (0.42) FLT3KMT2AMEN1MAPTCASP3
SCHEMBL5445078 0.78 CFTR (0.46) FLT3KMT2AMEN1
SCHEMBL5463015 0.76 AURKA (0.46) FLT3AURKAAURKBMAPK10KMT2A
SCHEMBL5447561 0.75 FLT3 (0.43) FLT3AURKBKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885AURKA 869/4885AURKB 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.